An Open-Label, Multicenter, Dose-Regimen Study Evaluating the Efficacy and Safety of Etanercept 50 mg Once-Weekly Dose in Japanese Subjects With Rheumatoid Arthritis.

Trial Profile

An Open-Label, Multicenter, Dose-Regimen Study Evaluating the Efficacy and Safety of Etanercept 50 mg Once-Weekly Dose in Japanese Subjects With Rheumatoid Arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2012

At a glance

  • Drugs Etanercept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Wyeth
  • Most Recent Events

    • 11 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top